TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38354904
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein treatment in patients without preexisting malnutrition
Study: 38354997
Drug: Gamification strategy
Normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gamification strategy to increase daily physical activity, including a wearable fitness tracker and a goal to increase daily step count by 33%-50% over 16 weeks.
Study: 38354997
Drug: Gamification strategy
Normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gamification strategy to increase daily physical activity.
Study: 38355180
Drug: WiserAD approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: WiserAD approach to antidepressant deprescribing
Study: 38355397
Drug: 5-mg midodrine
Normalized name: midodrine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg midodrine
Study: 38355421
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model based on demographic characteristics, work situation, daily lifestyle, and laboratory tests.
Study: 38355715
Drug: Kundalini yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kundalini yoga training (KY) - 60-min weekly classes for 12 weeks with daily 12-min homework practice.
Study: 38355715
Drug: Memory enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory enhancement training (MET) - 12 weekly in-person group classes with 12-min daily homework exercises.
Study: 38355814
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U300 (Gla-300)
Study: 38355932
Drug: Salivary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salivary iodine concentration (SIC) < 176 μg/L
Study: 38355932
Drug: Salivary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salivary iodine concentration (SIC) > 529 μg/L
Study: 38356344
Drug: Tα1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tα1 treatment
Study: 38356729
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with sintilimab, paclitaxel, and carboplatin (2 cycles, once every 21 days) followed by concurrent treatment with carboplatin and paclitaxel (5 cycles, once per week) concurrent with radiotherapy (50.4Gy in 28 fractions)
Study: 38356729
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy only (from previous studies)
Study: 38356837
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care and SMS reminder
Study: 38356864
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy in HDUs
Study: 38356864
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy in ICUs
Study: 38356882
Drug: Personalized digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized digital speech therapy application
Study: 38356882
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with a workbook
Study: 38356884
Drug: Ravulizumab (2,400-3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (2,400-3,000 mg loading dose on day 1, followed by 3,000-3,600 mg maintenance doses on day 15 and once every 8 weeks thereafter)
Study: 38356965
Drug: Entinostat 3-5
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat 3-5 mg and Capecitabine 800 mg
Study: 38357205
Drug: BCT-100 (1600U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCT-100 (1600U/kg iv weekly)
Study: 38357391
Drug: peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: peficitinib 100 mg
Study: 38357391
Drug: peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: peficitinib 150 mg
Study: 38357398
Drug: Half-dose BNT162b2
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose BNT162b2 (15 μg)
Study: 38357398
Drug: Full-dose BNT162b2
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose BNT162b2 (30 μg)
Study: 38357398
Drug: Half-dose BNT162b2
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose BNT162b2 (15 μg) in Gam-COVID-Vac-primed participants
Study: 38357398
Drug: Full-dose BNT162b2
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose BNT162b2 (30 μg) in Gam-COVID-Vac-primed participants
Study: 38357797
Drug: SAGE-324/BIIB124 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-324/BIIB124 (60 mg once daily for 28 days)
Study: 38357797
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 28 days)
Study: 38357820
Drug: BMS-986141 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986141 (4 mg single oral dose)
Study: 38357820
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ticagrelor (90 mg BID) and aspirin (75 mg QD)
Study: 38357820
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg BID)
Study: 38357820
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg QD)
Study: 38358253
Drug: Xanthohumol (XN)
Normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthohumol (XN) supplementation, dosage and duration not specified
Study: 38358334
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks
Study: 38358339
Drug: Zanidatamab (bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab (bispecific anti-HER2 antibody)
Study: 38358339
Drug: MET inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET inhibitors (single-agent and in combination with zanidatamab)
Study: 38358423
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (2.5 J, frequency 9.12 Hz, 904 nm for 10 min for 12 sessions)
Study: 38358542
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus bevacizumab (200 mg and 15 mg/kg respectively) combined with radiotherapy (30-50 Gy/10 fractions)
Study: 38358753
Drug: pegargiminase-chemotherapy (36.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegargiminase-chemotherapy (36.8 mg/m2 weekly intramuscularly)
Study: 38358753
Drug: pegargiminase-chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegargiminase-chemotherapy
Study: 38359838
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with psilocybin-assisted psychotherapy (PAP)
Study: 38360044
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IG)
Study: 38360182
Drug: Brolucizumab 6-mg
Normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab 6-mg
Study: 38360182
Drug: Aflibercept 2-mg
Normalized name: aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 2-mg
Study: 38360261
Drug: Initial antiseizure
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antiseizure medication (ASM)
Study: 38360334
Drug: CureSight (binocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: CureSight (binocular eye-tracking-based home treatment)
Study: 38360494
Drug: Daily washing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily washing
Study: 38360686
Drug: Multi-component pain
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component pain management pathway facilitated by a pain management coordinator including preoperative education, risk identification, personalized analgesic prescriptions, and continued support up to 8 weeks post-op.
Study: 38360739
Drug: ethinylestradiol/levonorgestrel 30/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinylestradiol/levonorgestrel 30/150 μg
Study: 38361371
Drug: Probiotic intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intervention, details on dosage and duration not specified
Study: 38362052
Drug: Multidomain intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidomain intervention through the tablet PC SUPERBRAIN application for 24 weeks, including managing metabolic and vascular risk factors, cognitive training, physical exercise, nutritional guidance, and boosting motivation.
Study: 38362338
Drug: M-atrial natriuretic
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-atrial natriuretic peptide (single subcutaneous injection)
Study: 38362377
Drug: Precision-based targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision-based targeted therapies
Study: 38362377
Drug: Precision-based targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision-based targeted therapies in HR+/HER2+ subtype
Study: 38362466
Drug: FLASH-RT (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLASH-RT (dose rate: 220-270 Gy/s)
Study: 38362466
Drug: CONV-RT (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONV-RT (dose rate: 0.03-0.06 Gy/sec)
Study: 38362629
Drug: hyaluronidase-facilitated subcutaneous
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG)
Study: 38362837
Drug: SAR439459 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR439459 administered intravenously at increasing doses every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W.
Study: 38362837
Drug: SAR439459 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR439459 22.5 mg/kg with cemiplimab 350 mg IV Q3W.
Study: 38362850
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant chemotherapy (AC)
Study: 38362850
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant chemotherapy (AC)
Study: 38363314
Drug: Post-treatment seizures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment seizures
Study: 38363314
Drug: Mothers having
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers having no formal education and lower household monthly income
Study: 38363571
Drug: COVID-19 positive
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 positive patients receiving chemotherapy (n=110)
Study: 38363577
Drug: Zilebesiran 150
Normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran 150 mg, once every 6 months
Study: 38363577
Drug: Zilebesiran 300
Normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran 300 mg, once every 3 months or every 6 months
Study: 38363577
Drug: Zilebesiran 600
Normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran 600 mg, once every 6 months
Study: 38363733
Drug: Universal testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal testing and treatment (UTT) as part of the community-level combination HIV prevention package.
Study: 38363772
Drug: Traditional bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional bread (200 g/d for 8 weeks)
Study: 38363772
Drug: Control bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control bread (200 g/d for 8 weeks)
Study: 38363950
Drug: Hip abductor
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip abductor and external rotator strengthening exercises with conventional physical therapy (CPT)
Study: 38363950
Drug: Proprioceptive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive training with conventional physical therapy (CPT)
Study: 38364020
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (minimum 50 l/min)
Study: 39318387
Drug: Single-agent cabozantinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent cabozantinib
Study: 38365118
Drug: Evenly distributing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evenly distributing protein across meals (25-30 g per meal)
Study: 38365173
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + WET (Written Exposure Therapy)
Study: 38365417
Drug: Tafenoquine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine administered to patients with G6PD normal status, aged ≥16 years, not pregnant or breastfeeding.
Study: 38365417
Drug: G6PD testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: G6PD testing before tafenoquine administration.
Study: 38365417
Drug: Primaquine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine administered to patients with intermediate or normal G6PD status, aged ≥6 months, not pregnant or breastfeeding >1 month.
Study: 38365437
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of comorbidities (e.g., cancer, obesity, organ transplant)
Study: 38365502
Drug: CT-P13 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 SC (body weight-based dosing every 2 weeks [Q2W]; W6-54)
Study: 38365502
Drug: CT-P13 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 IV (5 mg/kg Q8W; W6-22) then CT-P13 SC (Q2W; W30-54)
Study: 38365694
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) using 980 nm diode laser, 300 mW, twice weekly for 5 weeks (10 sessions)
Study: 38365694
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% triamcinolone acetonide three times daily with miconazole oral gel once daily for 4 weeks
Study: 38365744
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors
Study: 38365756
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment (both cohorts)
Study: 38365814
Drug: Model-informed precision
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-informed precision dosing (MIPD) of vancomycin targeting an AUC24h of 400 to 600 mg × h/L
Study: 39390583
Drug: Standard-of-care dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care dosing and monitoring according to institutional guidelines
Study: 38365814
Drug: Model-informed precision
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-informed precision dosing (MIPD) of vancomycin
Study: 38365853
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2i) treatment for 12 weeks
Study: 38365949
Drug: ganfeborole 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganfeborole 5 mg
Study: 38365949
Drug: ganfeborole 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganfeborole 15 mg
Study: 38365949
Drug: ganfeborole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganfeborole 30 mg
Study: 38365949
Drug: ganfeborole 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganfeborole 1 mg
Study: 38365951
Drug: Happy Mother-Healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happy Mother-Healthy Baby program (anxiety-focused cognitive behavioral therapy, six one-on-one sessions)
Study: 38365952
Drug: Lower-dose osocimab
Normalized name: Osocimab
DrugBank: Osocimab (DB14818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose osocimab
Study: 38365952
Drug: Higher-dose osocimab
Normalized name: Osocimab
DrugBank: Osocimab (DB14818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose osocimab
Study: 38366021
Drug: MTB advised
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTB advised molecular-guided treatment options
Study: 38366225
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of small and ultrasmall graphene oxide nanosheets at a concentration of 200 μg/m3
Study: 38366267
Drug: Ambrisentan (2.5/5/7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (2.5/5/7.5 or 10 mg/day)
Study: 38366324
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 20 μg
Study: 38366324
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (fentanyl 100 μg and lidocaine 80 mg)
Study: 38366591
Drug: BNT166a (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT166a (quadrivalent vaccine)
Study: 38366591
Drug: BNT166c (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT166c (trivalent vaccine)
Study: 38366591
Drug: BNT166a and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT166a and BNT166c (both vaccines)
Study: 38366621
Drug: Tofacitinib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (in treatment-naïve subpopulation)
Study: 38366621
Drug: TNFi (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi (in treatment-naïve subpopulation)
Study: 38366886
Drug: Apatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib plus toripalimab (250 mg apatinib per day plus 240 mg toripalimab on day 1 per 3 weeks)
Study: 38366886
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy (PC)
Study: 38366909
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (2 × 10^6 cells)
Study: 38366909
Drug: Medium-dose group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose group (20 × 10^6 cells)
Study: 38366909
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (80 × 10^6 cells)
Study: 38367207
Drug: 12-week timing
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week timing and coordination physical therapy intervention
Study: 38367405
Drug: On-treatment modified
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment modified Glasgow prognostic score (mGPS) assessed at week six in atezolizumab-treated subgroup
Study: 38367405
Drug: On-treatment modified
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment modified Glasgow prognostic score (mGPS)
Study: 38367750
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg vaginal misoprostol (subgroup: multiparous patients)
Study: 38367750
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vaginal misoprostol (subgroup: multiparous patients)
Study: 38367750
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (25 μg and 50 μg)
Study: 38367966
Drug: Nudge intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nudge intervention consisting of three text message reminders with four behavioural nudges: (1) social norm messages, (2) different messengers through links to short educational videos, (3) a pledge to have their child vaccinated, (4) information salience through links to guidelines and vaccine safety information.
Study: 38368603
Drug: Somapacitan (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.16 mg/kg/week) after continuous treatment
Study: 38368603
Drug: Somapacitan (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.16 mg/kg/week) after switch from daily GH
Study: 38368901
Drug: Targeted anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted anticoagulation according to TRiP(cast) score (no prescription if score <7, anticoagulation if score ≥7)
Study: 38368901
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (anticoagulation prescription according to physician's usual practice)
Study: 38369233
Drug: Parenteral thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral thiamine (100 mg daily) for ≥3 days
Study: 38369528
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate solution (RAS)
Study: 38369573
Drug: PRV-101 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRV-101 (low dose)
Study: 38369573
Drug: PRV-101 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRV-101 (high dose)
Study: 38369573
Drug: PRV-101 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRV-101 (low dose and high dose)
Study: 38369805
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment (not specified, but includes proteasome inhibitor-based combination therapy)
Study: 38369805
Drug: Proteasome inhibitor
Normalized name: Proteasome inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteasome inhibitor (PI)-based combination therapy